There is an urgent need for new ways to assess the biological properties of prostate cancers that can be applied to needle biopsies. This research program will identify new molecular markers of human prostate cancer as new diagnostic and prognostic factors for clinical translation to the outcome for individual patients. These molecular markers will be correlated with the response and biological properties of prostate cancer such as structure, growth immortalization, invasion, and metastasis. Studies will focus on cell structural alterations, DNA instability and telomerase activity that are applicable to zonal analysis of needle biopsies. Alterations in nuclear and cellular shapes have long been recognized as one of the very earliest and most common cellular events associated with any type of carcinogenesis, This morphological transformation involves variation in nuclear morphology and chromatin patterns that are distinguishing features in the cytopathological identification of cancer cells. We have correlated quantitative morphometry of nuclear and chromatin changes with prognosis in human prostate cancer, and propose here to identify their molecular components, The shape of the nucleus appears to be defined by an internal nuclear scaffolding system that forms an organizing framework that we termed the nuclear matrix. The nuclear matrix provides a tissue specific 3- dimensional organization of DNA that dictates the higher order structure of the genome. The protein components of the matrix are tissue- and tumor-specific and provide DNA binding sites that define the spatial locations for tissue specific gene expression with actively expressed genes located on the nuclear matrix. DNA synthesis occurs at fixed replicating sites located near these matrix attachment sites. Telomeres are tightly attachments to the nuclear matrix. The nuclear matrix is ideally positioned to play a critical role in providing structural sites for organizing many nuclear events involved in DNA functions. Therefore, in carcinogenesis and tumor progression, the aberrations seen in the shapes of the cancer nuclei may be of prime importance in disturbing normal DNA functions that are organized on the nuclear matrix. We have observed specific changes occurring in nuclear matrix proteins associated with prostate cancer in both humans and animals. A new matrix protein, PC-1, appears in human prostate cancer, while other matrix proteins like NBP-4, disappear, Antibodies have been made to these proteins that will assist in their evaluation. We have also observed shortening in telomere lengths in human prostate cancer that accompanies induction of telomerase activity. These nuclear matrix proteins and telomerase activity will be applied to needle biopsies and translated into clinical evaluation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-07
Application #
6203264
Study Section
Project Start
1999-08-04
Project End
2000-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Joshu, Corinne E; Peskoe, Sarah B; Heaphy, Christopher M et al. (2018) Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate 78:233-238
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Das, Swadesh K; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Res 78:2852-2863
Karnes, R Jeffrey; Choeurng, Voleak; Ross, Ashley E et al. (2018) Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 73:168-175

Showing the most recent 10 out of 750 publications